GlassScriptPhysician profile
Michael Jerome Depenbusch
NPI 1003897794
$1,605.18
in general payments reported to CMS, 2019-2025
25 companies · $68.02 in 2025
The $68.02 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $146 · 2021: $182 · 2022: $354 · 2023: $135 · 2024: $133 · 2025: $68.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292 · Honoraria: $25.59 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.49 |
| Honoraria | $25.59 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $433.43 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $321.83 | 2022-2025 | Envista Envy, Stellaris, Miebo |
| Hoffmann-La Roche Limited | $136.30 | 2019 | |
| Allergan, INC. | $115.39 | 2019-2021 | |
| Alcon Vision LLC | $113.81 | 2022-2024 | Hydrus Microstent |
| Rxsight INC | $71.15 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Contact Lens |
| Glaukos Corporation | $68.13 | 2021-2023 | |
| Dutch Ophthalmic, USA | $51.55 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $41.00 | 2019 | |
| Shire North American Group INC | $40.75 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $36.90 | 2020-2025 | Tecnis Simplicity |
| Kala Pharmaceuticals, INC. | $35.61 | 2019-2021 | |
| Omeros Corporation | $32.81 | 2019 | |
| Notal Vision, INC. | $32.11 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $17.23 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.81 | 2025 | Tepezza |
| Thea Pharma INC. | $15.58 | 2023 | |
| Novartis Pharmaceuticals Corporation | $12.92 | 2019 | |
| Akorn Operating Company LLC | $11.87 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Depenbusch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.